Biotechnology
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove […]
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from […]
Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]
Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]
Read More
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. The move […]
Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]
Read More
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. Lilly and its chief rival, Novo Nordisk, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But […]
Read More
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, […]
Read More
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments. In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]
Read More
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
A researcher works in the lab at the Moderna headquarters in Cambridge, Massachusetts, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency’s earlier decision to refuse to accept the application in a move […]
Read More